RecruitingPhase 2NCT06963177

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.

Enrollment

200 participants

Start Date

May 26, 2025

Study Type

INTERVENTIONAL

Conditions

Endometriosis-related Pain

Summary

This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GenSci048 and a drug called Placebo for people with endometriosis-related pain. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 49 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.